Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 809 results for "iibs"

NEOVACS Completes Enrollment for Phase IIB of TNF-Kinoid in Rheumatoid Arthritis

Akebia completes enrollment in Phase IIb anemia associated wit...

Akebia Therapeutics, Inc., a biopharmaceutical company, has completed enrollment in its ongoing 200-patient Phase IIb study of AKB-6548 for the treatment of anemia associated with chronic kidney disease, or CKD, in patients who are not dependent on ..., 10 minutes ago

59 images for iibs

Talking Points Memo, 1 week ago
ABC News 4 Charleston, 3 days ago
MSN Canada, 6 days ago
Bioscience Technology Online, 1 week ago
Scottrade, 2 weeks ago
BusinessWeek, 2 weeks ago
Formulary Journal, 2 weeks ago
MSN Canada, 4 weeks ago
MSN Canada, 1 month ago
BusinessWeek, 1 month ago

DuPont Fabros Technology, Inc. Reports First Quarter 2014 Results

World News: 12:00 GMT Thursday 24th April 2014 . [ DuPont Fabros Technology, Inc. via PR Newswire via SPi World News ] WASHINGTON , April24, 2014DuPont Fabros Technology, Inc. (NYSE: DFT) is reporting results for the quarter ended March31, 2014.
 SPi World News3 hours ago /C O R R E C T I O N -- DuPont Fabros Technology, Inc./  Sys-Con Australia16 minutes ago

Cmed invitée à se joindre aux conférenciers du Forum européen sur les données cliniques

HORSHAM, Angleterre--( BUSINESS WIRE )--Cmed Clinical Services a annoncé aujourdhui quelle présentera lors du Forum européen sur les données cliniques, qui se tiendra les 7 et 8 mai 2014 à Bruxelles. La participation de la ...
 Business Wire50 minutes ago Cmed erhält Einladung als Referent des European Clinical Data Forum  Business Wire50 minutes ago Cmed Invited to Join Speaker Line-Up at European Clinical Data Forum  Business Wire4 hours ago

AstraZeneca First Quarter 2014 financial results

Revenue up 3% at constant exchange rates (CER) in first quarter. Consolidation of full diabetes franchise contributed 2 percentage points of revenue growth. All growth platforms growing strongly. • Brilinta sales $99 million (+94% CER), diabetes ...
 FiercePharma1 hour ago 1st Quarter Results  TrustNet8 hours ago AstraZeneca PLC 1st Quarter Results  ADVFN UK8 hours ago

Alcobra Ltd. to Present New Data for Metadoxine Extended Release (MDX) at Upcoming Meetings

04/24/2014 | 08:02am US/Eastern Recommend: TEL AVIV, Israel , April 24, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with ...
 4 Traders2 hours ago Alcobra Ltd. Submits Protocol to FDA for Phase IIb Clinical Study of Metadoxine Extended Release (MDX) in the Treatment of Fragile X Syndrome  OSIX News1 week ago Alcobra submits protocol to US FDA for Phase IIb MDX trial to treat Fragile X Syndrome  Pharmaceutical Technology1 week ago Alcobra Ltd submits protocol to FDA for Phase IIb clinical study of Metadoxine Extended Release in treatment of Fragile X Syndrome  Reuters UK1 week ago

Sarepta Therapeutics Erupts On Optimism Over Muscular Dystrophy Drug; Stock Up +39.26% At Market Close (April 21, 2014)

Sarepta Therapeutics Announces Plans to Submit New Drug Application to FDA for Eteplirsen for the Treatment of Duchenne Muscular Dystrophy by Year End 2014 CAMBRIDGE, Mass., Apr 21, 2014 (BUSINESS WIRE) -- Sarepta Therapeutics, Inc. SRPT +55.74% , a ...
 BioSpace2 days ago Sarepta plans FDA filing for Duchenne muscular dystrophy drug eteplirsen by year end, shares rise  FirstWord Pharma3 days ago Sarepta Therapeutics plans to submit eteplirsen NDA for treatment of Duchenne muscular dystrophy  News-Medical.Net3 days ago Sarepta Therapeutics Reports Plans to Submit New Drug Application to FDA for Eteplirsen for the Treatment of Duchenne Muscular Dystrophy by Year End [Health & Beauty Close - Up]  Pharmacy Choice3 hours ago

GSI to establish Gondwana Research Centre to boost exploration

The Geological Survey of India (GSI) has decided to set up a Gondwana Research Centre in this city to promote its coal exploration activities in the country. The proposed research facility to be established under supervision of Mission II-B (Natural ...
 NetIndia123.com3 hours ago

ARCA screens first patient in Phase IIB/III atrial fibrillation trial

ARCA biopharma, Inc., a developer of genetically targeted therapies for cardiovascular diseases, has screened first patient in GENETIC-AF, its Phase IIB/III adaptive design clinical trial to evaluate Gencaro as a treatment for the prevention of ...
 Individual.com5 hours ago Glycotope enrolls and treats first patients in Phase IIb SCCHN trial  Individual.com6 days ago Glycotope doses first patients in Phase IIb trial of CetuGEX to treat SCCHN  Pharmaceutical Business Review2 weeks ago Norgine and Innovacell dose first patient in faecal incontinence study  Individual.com3 weeks ago

Anergis Completes Enrolment In The Long-Term Efficacy Trial Of Lead Compound AllerT

EPALINGES, Switzerland, April 23 , 201 4 Anergis, a company discovering and developing proprietary allergy vaccines, today announced tha t it has completed the enrolment of 196 subjects in the long - term efficacy trial of its birch pollen allergy ...
 BioSpace19 hours ago

Frequent Mutations in EGFR, KRAS and TP53 Genes in Human Lung Cancer Tumors Detected by Ion Torrent DNA Sequencing

Affiliation: The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China X Jianhui Sheng, Affiliation: The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China X Chuanning Tang, ...
 PLoS Medicine8 hours ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less